Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Ascending Dose Study of LY3209590 in Japanese Patients With Type 2 Diabetes Mellitus
jRCT2080223988Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing LY3209590 with Placebo (2 arms). Primary endpoints: Safety and tolerability of LY3209590, Pharmacokinetics of LY3209590 and 1 more. Started Jul 2018; status: recruiting.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223988.